127 related articles for article (PubMed ID: 37030166)
21. The TGF-β co-receptor, CD109, promotes internalization and degradation of TGF-β receptors.
Bizet AA; Liu K; Tran-Khanh N; Saksena A; Vorstenbosch J; Finnson KW; Buschmann MD; Philip A
Biochim Biophys Acta; 2011 May; 1813(5):742-53. PubMed ID: 21295082
[TBL] [Abstract][Full Text] [Related]
22. SWATH™- and iTRAQ-based quantitative proteomic analyses reveal an overexpression and biological relevance of CD109 in advanced NSCLC.
Zhang F; Lin H; Gu A; Li J; Liu L; Yu T; Cui Y; Deng W; Yan M; Li J; Yao M
J Proteomics; 2014 May; 102():125-36. PubMed ID: 24667143
[TBL] [Abstract][Full Text] [Related]
23. CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer.
Adachi K; Sakurai Y; Ichinoe M; Tadehara M; Tamaki A; Kesen Y; Kato T; Mii S; Enomoto A; Takahashi M; Koizumi W; Murakumo Y
Virchows Arch; 2022 Apr; 480(4):819-829. PubMed ID: 34762199
[TBL] [Abstract][Full Text] [Related]
24. Transgenic mice overexpressing CD109 in the epidermis display decreased inflammation and granulation tissue and improved collagen architecture during wound healing.
Vorstenbosch J; Gallant-Behm C; Trzeciak A; Roy S; Mustoe T; Philip A
Wound Repair Regen; 2013; 21(2):235-46. PubMed ID: 23438099
[TBL] [Abstract][Full Text] [Related]
25. CD109 mediates tumorigenicity and cancer aggressiveness via regulation of EGFR and STAT3 signalling in cervical squamous cell carcinoma.
Mo XT; Leung TH; Tang HW; Siu MK; Wan PK; Chan KK; Cheung AN; Ngan HY
Br J Cancer; 2020 Sep; 123(5):833-843. PubMed ID: 32507856
[TBL] [Abstract][Full Text] [Related]
26. CD109 and squamous cell carcinoma.
Qi R; Dong F; Liu Q; Murakumo Y; Liu J
J Transl Med; 2018 Apr; 16(1):88. PubMed ID: 29625613
[TBL] [Abstract][Full Text] [Related]
27. Identification of CD109 as part of the TGF-beta receptor system in human keratinocytes.
Finnson KW; Tam BY; Liu K; Marcoux A; Lepage P; Roy S; Bizet AA; Philip A
FASEB J; 2006 Jul; 20(9):1525-7. PubMed ID: 16754747
[TBL] [Abstract][Full Text] [Related]
28. CD109 overexpression ameliorates skin fibrosis in a mouse model of bleomycin-induced scleroderma.
Vorstenbosch J; Al-Ajmi H; Winocour S; Trzeciak A; Lessard L; Philip A
Arthritis Rheum; 2013 May; 65(5):1378-83. PubMed ID: 23436317
[TBL] [Abstract][Full Text] [Related]
29. Suppression of skin tumorigenesis in CD109-deficient mice.
Sunagawa M; Mii S; Enomoto A; Kato T; Murakumo Y; Shiraki Y; Asai N; Asai M; Nagino M; Takahashi M
Oncotarget; 2016 Dec; 7(50):82836-82850. PubMed ID: 27756876
[TBL] [Abstract][Full Text] [Related]
30. Elevation of CD109 promotes metastasis and drug resistance in lung cancer via activation of EGFR-AKT-mTOR signaling.
Lee KY; Shueng PW; Chou CM; Lin BX; Lin MH; Kuo DY; Tsai IL; Wu SM; Lin CW
Cancer Sci; 2020 May; 111(5):1652-1662. PubMed ID: 32133706
[TBL] [Abstract][Full Text] [Related]
31. Significance of perivascular tumour cells defined by CD109 expression in progression of glioma.
Shiraki Y; Mii S; Enomoto A; Momota H; Han YP; Kato T; Ushida K; Kato A; Asai N; Murakumo Y; Aoki K; Suzuki H; Ohka F; Wakabayashi T; Todo T; Ogawa S; Natsume A; Takahashi M
J Pathol; 2017 Dec; 243(4):468-480. PubMed ID: 28888050
[TBL] [Abstract][Full Text] [Related]
32. Reduced expression of CD109 in tumor-associated endothelial cells promotes tumor progression by paracrine interleukin-8 in hepatocellular carcinoma.
Ye BG; Sun HC; Zhu XD; Chai ZT; Zhang YY; Ao JY; Cai H; Ma DN; Wang CH; Qin CD; Gao DM; Tang ZY
Oncotarget; 2016 May; 7(20):29333-45. PubMed ID: 27121053
[TBL] [Abstract][Full Text] [Related]
33. CD109 deficiency induces osteopenia with an osteoporosis-like phenotype in vivo.
Mii S; Hoshino A; Enomoto A; Murakumo Y; Ito M; Yamaguchi A; Takahashi M
Genes Cells; 2018 Jul; 23(7):590-598. PubMed ID: 29767469
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of CD109 expression in myxofibrosarcoma.
Emori M; Tsukahara T; Murata K; Sugita S; Sonoda T; Kaya M; Soma T; Sasaki M; Nagoya S; Hasegawa T; Wada T; Sato N; Yamashita T
J Surg Oncol; 2015 Jun; 111(8):975-9. PubMed ID: 26031650
[TBL] [Abstract][Full Text] [Related]
35. CD109 is a potential target for triple-negative breast cancer.
Tao J; Li H; Li Q; Yang Y
Tumour Biol; 2014 Dec; 35(12):12083-90. PubMed ID: 25149155
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical detection of bone morphogenetic proteins in bone and soft-tissue sarcomas.
Yoshikawa H; Rettig WJ; Lane JM; Takaoka K; Alderman E; Rup B; Rosen V; Healey JH; Huvos AG; Garin-Chesa P
Cancer; 1994 Aug; 74(3):842-7. PubMed ID: 8039112
[TBL] [Abstract][Full Text] [Related]
37. CD109 is a novel marker for squamous cell/adenosquamous carcinomas of the gallbladder.
Dong F; Lu C; Chen X; Guo Y; Liu J
Diagn Pathol; 2015 Aug; 10():137. PubMed ID: 26249215
[TBL] [Abstract][Full Text] [Related]
38. High-level expression of CD109 is frequently detected in lung squamous cell carcinomas.
Sato T; Murakumo Y; Hagiwara S; Jijiwa M; Suzuki C; Yatabe Y; Takahashi M
Pathol Int; 2007 Nov; 57(11):719-24. PubMed ID: 17922683
[TBL] [Abstract][Full Text] [Related]
39. Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-b as Involved in the Pathogenesis of Osteosarcoma.
Yang R; Piperdi S; Zhang Y; Zhu Z; Neophytou N; Hoang BH; Mason G; Geller D; Dorfman H; Meyers PA; Healey JH; Phinney DG; Gorlick R
Clin Orthop Relat Res; 2016 Jan; 474(1):178-89. PubMed ID: 26463566
[TBL] [Abstract][Full Text] [Related]
40. CD109 promotes the tumorigenic ability and metastatic motility of pancreatic ductal adenocarcinoma cells.
Hatsuzawa Y; Yamaguchi K; Takanashi T; Sato I; Tamai K; Mochizuki M; Iwai W; Wakui Y; Abue M; Yamamoto K; Yasuda J; Mizuma M; Unno M; Sugamura K
Pancreatology; 2020 Apr; 20(3):493-500. PubMed ID: 32007357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
